Pan American League of Associations for Rheumatology guidelines for the treatment of giant cell arteritis. (December 2022)

• Record Type: Journal Article
• Authors: Scolnik, Marina; Brance, Maria L; Fernández-Ávila, Daniel G; Inoue Sato, Emilia; de Souza, Alexandre W S; Magri, Sebastián J; Saldarriaga-Rivera, Lina M; Ugarte-Gil, Manuel F; Flores-Suarez, Luis F; Babini, Alejandra; Zamora, Natalia V; Acosta Felquer, María L; Vergara, Facundo; Carlevaris, Leandro; Scarafia, Santiago; Soriano Guppy, Enrique R; Unizony, Sebastian
• Is Part Of: Lancet. Volume 4:Number 12(2022)
• Page Start: e864
• Page End: e872
• Publication Date: 2022-12
• Subjects: Rheumatology -- periodicals; 616.72305
• DOI: 10.1016/S2665-9913(22)00260-0
• Languages: English
• ISSNs: 2665-9913

Abstract

Summary: Considerable variability exists in the way that health-care providers treat patients with giant cell arteritis in Latin America, with patients commonly exposed to excessive amounts of glucocorticoids. In addition, large health disparities prevail in this region due to socioeconomic factors, which influence access to care, including biological treatments. For these reasons, the Pan American League of Associations for Rheumatology developed the first evidence-based giant cell arteritis treatment guidelines tailored for Latin America. A panel of vasculitis experts from Mexico, Colombia, Peru, Brazil, and Argentina generated clinically meaningful questions related to the treatment of giant cell arteritis in the population, intervention, comparator, and outcome (PICO) format. Following the grading of recommendations, assessment, development, and evaluation methodology, a team of methodologists did a systematic literature search, extracted and summarised the effects of the interventions, and graded the quality of the evidence. The panel of vasculitis experts voted on each PICO question and made recommendations, which required at least 70% agreement among the voting members to be included in the guidelines. Nine recommendations and one expert opinion statement for the treatment of giant cell arteritis were developed considering the most up-to-date evidence and the socioeconomic characteristics of Latin America. These recommendations include guidance for the use of glucocorticoids, tocilizumab, methotrexate, and aspirin for patients with giant cell arteritis.